Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Cadila Healthcare...

    Cadila Healthcare Ankleshwar facility successfully completes USFDA inspection

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-01T09:25:35+05:30  |  Updated On 16 Aug 2021 2:59 PM IST

    "The United States Food and Drug Administration (USFDA) inspected the company's active pharmaceutical ingredient manufacturing facility located at Ankleshwar from July 22 to July 26, 2019," Cadila Healthcare added.


    New Delhi: Drug firm Cadila Healthcare recently said it has received no observations from the US health regulator for the inspection of its manufacturing plant at Ankleshwar in Gujarat.


    "Drug firm Cadila Healthcare on July 26 said its manufacturing plant at Ankleshwar in Gujarat has completed inspection by the US health regulator with no observations," the company said in a filing.


    "The United States Food and Drug Administration (USFDA) inspected the company's active pharmaceutical ingredient manufacturing facility located at Ankleshwar from July 22 to July 26, 2019," Cadila Healthcare added.


    Read Also: Cadila Healthcare gets 11 USFDA observations for St Louis facilities


    This audit covered both Units I and II. At the end of the inspection, no 483 observations were issued, it added.




    The USFDA Form 483 is officially called a "Notice of Inspectional Observations," commonly referred to simply as a "483." The 483 is issued at the end of an on-site inspection if the FDA field investigator observed deficiencies in the quality system or conditions that violate the Food, Drug, or Cosmetic Act.


    Medical Dialogues had earlier reported that Cadila Healthcare had received Establishment Inspection Report from USFDA with voluntary action indicated (VAI) classification for its Ahmedabad SEZ facility.


    The company is headquartered at Ahmedabad in Gujarat state of western India. It is a manufacturer of generic drugs and was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi.


    Read Also: Cadila Healthcare gets EIR report on Ahmedabad SEZ facility

    AnkleshwarCadilaCadila Gujarat unitCadila HealthcareHealthcarepharmapharma companypharma newspharma news indiaUSFDAUSFDA inspection
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok